Michael Klichinsky's Insider Trades & SAST Disclosures

Michael Klichinsky's most recent trade in Carisma Therapeutics Inc was a trade of 56,982 Stock Option (right to buy) done . Disclosure was reported to the exchange on Oct. 7, 2025.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Carisma Therapeutics Inc
Michael Klichinsky Chief Scientific Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 07 Oct 2025 56,982 0 - - Stock Option (right to buy)
Carisma Therapeutics Inc
Michael Klichinsky Chief Scientific Officer Sale of securities on an exchange or to another person at price $ 0.25 per share. 07 Oct 2025 56,982 0 - 0.3 14,485 Common Stock
Carisma Therapeutics Inc
Michael Klichinsky Chief Scientific Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.11 per share. 07 Oct 2025 56,982 56,982 - 0.1 6,268 Common Stock
Carisma Therapeutics Inc
Michael Klichinsky Chief Scientific Officer Sale of securities on an exchange or to another person at price $ 0.25 per share. 01 Oct 2025 200,000 119,347 - 0.3 50,860 Common Stock
Carisma Therapeutics Inc
Michael Klichinsky Chief Scientific Officer Sale of securities on an exchange or to another person at price $ 0.26 per share. 01 Oct 2025 165,000 319,347 - 0.3 42,405 Common Stock
Carisma Therapeutics Inc
Michael Klichinsky Chief Scientific Officer Sale of securities on an exchange or to another person at price $ 0.26 per share. 01 Oct 2025 119,347 0 - 0.3 31,078 Common Stock
Carisma Therapeutics Inc
Michael Klichinsky Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jan 2025 221,000 221,000 - - Stock Option (Right to Buy)
Carisma Therapeutics Inc
Michael Klichinsky Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jun 2024 85,000 85,000 - - Stock Option (Right to Buy)
Carisma Therapeutics Inc
Klichinsky Michael Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2024 170,500 170,500 - - Stock Option (Right to Buy)
Carisma Therapeutics Inc
Michael Klichinsky Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Jun 2023 238,000 238,000 - - Stock Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades